Literature DB >> 18240060

Evolution of HIV dementia with HIV infection.

Avindra Nath1, Nicoline Schiess, Arun Venkatesan, Jeffrey Rumbaugh, Ned Sacktor, Justin McArthur.   

Abstract

Dementia remains one of the most fearsome complications of HIV infection. It also poses a significant challenge for the clinician both in terms of diagnosis and treatment. The use of antiretroviral agents has led to a decrease in the incidence of HIV dementia but the prevalence of milder forms of neurocognitive impairment has increased. Occasionally, the immune reconstitution caused by these agents may target the brain leading to a syndrome characterized by a severe, progressive and often fatal dementia. The progression of HIV dementia may also be determined by host and viral genetic factors, and the existence of co-morbid factors such as drug abuse, hepatitis C infection and aging. Oxidative stress markers appear to be predictive of active dementia. However, currently there is no specific treatment available for HIV dementia.

Entities:  

Mesh:

Year:  2008        PMID: 18240060     DOI: 10.1080/09540260701861930

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  67 in total

Review 1.  Neuropsychiatric complications of aging with HIV.

Authors:  Crystal C Watkins; Glenn J Treisman
Journal:  J Neurovirol       Date:  2012-05-30       Impact factor: 2.643

Review 2.  Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms.

Authors:  Shilpa Buch; Honghong Yao; Minglei Guo; Tomohisa Mori; Blaise Mathias-Costa; Vijeta Singh; Pankaj Seth; John Wang; Tsung-Ping Su
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.

Authors:  Paul J Pistell; Sunita Gupta; Alecia G Knight; Michelle Domingue; Romina M Uranga; Donald K Ingram; Indu Kheterpal; Carmen Ruiz; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  Antiviral Res       Date:  2010-10-21       Impact factor: 5.970

Review 4.  Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders.

Authors:  Suman Jayadev; Gwenn A Garden
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-17       Impact factor: 4.147

5.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 6.  A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.

Authors:  Stephanie D Kraft-Terry; Shilpa J Buch; Howard S Fox; Howard E Gendelman
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

Review 7.  Does highly active antiretroviral therapy improve neurocognitive function? A systematic review.

Authors:  John A Joska; Hetta Gouse; Robert H Paul; Dan J Stein; Alan J Flisher
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

Review 8.  Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND.

Authors:  Bezawit Megra; Eliseo Eugenin; Toni Roberts; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-25       Impact factor: 4.147

9.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

10.  In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain.

Authors:  Eva-Maria Ratai; Sarah J Pilkenton; Jane B Greco; Margaret R Lentz; Jeffrey P Bombardier; Katherine W Turk; Julian He; Chan-Gyu Joo; Vallent Lee; Susan Westmoreland; Elkan Halpern; Andrew A Lackner; R Gilberto González
Journal:  BMC Neurosci       Date:  2009-06-22       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.